A Preliminary Study for the Rating of Pharmacological Effect with Aberrant Behavior Checklist in Children with Autistic Disorder
![]() |
Moon, Duk-Soo
(Department of Psychiatry, Kyungpook National University School of Medicine)
Chung, Un-Sun (Department of Psychiatry, Kyungpook National University School of Medicine) Jung, Sung Hoon (Department of Psychiatry, Kyungpook National University School of Medicine) Cho, Ah Rang (Department of Psychiatry, Kyung Hee University School of Medicine) Bahn, Geon Ho (Department of Psychiatry, Kyung Hee University School of Medicine) |
1 | American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington DC: American Psychiatric Press;2000. p.69-84. |
2 | Hillman JL, Neubronder J, Snyder SJ. Childhood Autism. New York: Taylor & Francis Group;2007. p.49. |
3 | Volkmar F, Cook EH Jr, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999;38(12 Suppl):32S-54S. DOI ScienceOn |
4 | Scahill L, Martin A. Psychopharmacology. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders. Hoboken: Wiley;2005. p.1102-1122. |
5 | Nazeer A, Ghaziuddin M. Autism spectrum disorders: clinical features and diagnosis. Pediatr Clin North Am 2012;59:19-25, ix. DOI ScienceOn |
6 | Cho IH, Yoo HK, Son JW, Yoo HJ, Koo YJ, Chung US, et al. The Korean practice parameter for the treatment of pervasive developmental disorders: pharmacological treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:109-116. 과학기술학회마을 |
7 | Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012;129:e771-e784. DOI ScienceOn |
8 | Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat 2008;4:723-730. |
9 | Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-e641. DOI ScienceOn |
10 | Myers SM, Johnson CP; American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007;120:1162-1182. DOI ScienceOn |
11 | Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007;37:367-373. DOI |
12 | Karabekiroglu K, Aman MG. Validity of the aberrant behavior checklist in a clinical sample of toddlers. Child Psychiatry Hum Dev 2009;40:99-110. DOI |
13 | Glascoe FP. Early detection of developmental and behavioral problems. Pediatr Rev 2000;21:272-279; quiz 280. DOI |
14 | Aman MG, Singh NN, Stewart AW, Field CJ. Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic 1985; 89:492-502. |
15 | Scahill L, Hallett V, Aman MG, McDougle CJ, Eugene Arnold L, et al. Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 2013;43:739-746. DOI |
16 | Aman MG, Singh NN, Turbott SH. Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. Am J Ment Defic 1987;92:237-240. |
17 | Marshburn EC, Aman MG. Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation. J Autism Dev Disord 1992;22:357-373. DOI |
18 | Yoo HJ, Cho IH, Koo YJ, Yoo HI, Son JW, Chung US, et al. The Korean practice parameter for the treatment of pervasive developmental disorders: diagnosis and assessment. J Korean Acad Child Adolesc Psychiatry 2007;18:97-108. 과학기술학회마을 |
19 | King BH. Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord 2000;30:439-445. DOI ScienceOn |
20 | Freund LS, Reiss AL. Rating problem behaviors in outpatients with mental retardation: use of the Aberrant Behavior Checklist. Res Dev Disabil 1991;12:435-451. DOI ScienceOn |
21 | Brinkley J, Nations L, Abramson RK, Hall A, Wright HH, Gabriels R, et al. Factor analysis of the aberrant behavior checklist in individuals with autism spectrum disorders. J Autism Dev Disord 2007;37: 1949-1959. DOI |
22 | Hollander E, Phillips A, King BH, Guthrie D, Aman MG, Law P, et al. Impact of recent findings on study design of future autism clinical trials. CNS Spectr 2004;9:49-56. DOI |
23 | Chavez B, Chavez-Brown M, Sopko MA Jr, Rey JA. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs 2007;9:249-266. DOI ScienceOn |
24 | McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321. DOI ScienceOn |
25 | Dean AJ, Wragg J, Draper J, McDermott BM. Predictors of medication adherence in children receiving psychotropic medication. J Paediatr Child Health 2011;47:350-355. DOI ScienceOn |
26 | Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55 Suppl:13-17. |
![]() |